Sun Pharma Q4 FY24 Results, Sun pharma Market News: Mumbai-headquartered Sun Pharma—the country’s largest pharmaceutical company—is scheduled to report its financial results for the quarter as well as the year ended March 31, 2024, on Wednesday, May 21. Analysts expect the lender to stage a steady financial performance for the final three months of the financial year 2023-24 (FY24).
Read More: JSW Cement to invest Rs 3K cr for Nagaur plant
According to Zee Business research, Sun Pharma is likely to register a consolidated net profit of Rs 2,347 crore for the January-March period, which translates into an increase of 18.4 per cent over the corresponding period a year ago. The analysts expect the pharmaceutical major to clock 12 per cent year-on-year growth in revenue to Rs 12,240 crore for the March quarter.
Read More: Gold Rate Rises In India: Check 22 Carat Price In Your City On May 21
Sun Pharma is estimated to register Rs 3,199 crore in its fourth-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), as against Rs 2,802 crore a year ago, while maintaining its margin—a key measure of profitability for businesses—at 26 per cent on a year-on-year basis.
